13 results
8-K
EX-99.1
BHVN
Biohaven Ltd.
27 Sep 23
Regulation FD Disclosure
6:58am
Label warnings for skin discoloration Black box warning for retinal abnormalities/vision loss FDA Drug Safety Communication: Potiga (ezogabine) [04-26
424B4
BHVN
Biohaven Ltd.
24 Oct 22
Prospectus supplement with pricing info
9:38am
by regulatory authorities of additional warnings on the label, such as a “black box” warning or contraindication;
requirement that we implement a REMS
S-1/A
BHVN
Biohaven Ltd.
20 Oct 22
IPO registration (amended)
10:00am
or the manufacturing process for any component thereof;
requirement by regulatory authorities of additional warnings on the label, such as a “black
S-1
w2g18 ss4
18 Oct 22
IPO registration
4:03pm
DRS
h2zc7mbq
11 Oct 22
Draft registration statement
12:00am
10-12B/A
EX-99.1
mzxsu2wat7m9 efiu8a
20 Sep 22
Registration of securities (amended)
6:30am
10-12B/A
EX-99.1
j6v766dg4fde
14 Sep 22
Registration of securities (amended)
5:25pm
10-12B/A
EX-99.1
dznl6tl4cbxujg5nnmg
7 Sep 22
Registration of securities (amended)
7:26am
10-12B/A
EX-99.1
5isy7r 6w
24 Aug 22
Registration of securities (amended)
5:03pm
10-12B
EX-99.1
scgfja 6r
10 Aug 22
Registration of securities
5:07pm
DRS
EX-99.1
l7e3e3whuh 69qe8h61
1 Jul 22
Draft registration statement
12:00am
- Prev
- 1
- Next